⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 10, 2024Investigational New DrugsOpen Access

A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants

Pranav Gupta Manash Chatterjee Yeonil Kim Kathleen Deschamps Lieselotte Lemoine Kristien Van Dyck Catherine Z. Matthews Sylvie Rottey Aubrey Stoch Eseng Lai

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

This phase 1 first-in-human study evaluated the safety, tolerability, and pharmacokinetics of MK-1088, a novel, small-molecule dual inhibitor of adenosine A

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gupta et al. (2024) studied this question.

synapsesocial.com/papers/68e5cc6bb6db643587562c94 https://doi.org/10.1007/s10637-024-01462-y

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Discovery of MK-1088 as a Potent A <sub>2A</sub> /A <sub>2B</sub> Adenosine Receptor Dual-Antagonist for Cancer ImmunotherapyOriginal Research · 2026 · 2 citations
2ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.2024 · 4 citations
3First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumorsEarly-Phase Clinical Trial · 2026 · 2 citations
4Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical TrialHuman Clinical Trial · 2026
5Safety and Pharmacokinetics of MK-8527 in Adults Without HIV.2025 · 4 citations
6Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease2024 · 12 citations
7Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteersother · 1999 · 8 citations
8Abstract LB166: Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist2024 · 1 citations
9Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verificationInvestigational New Drugs · 2026
10Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescenceInvestigational New Drugs · 2026

More from Investigational New Drugs

More from Merck & Co., Inc., Rahway, NJ, USA (United States)

More from Ghent University Hospital

More from MSD (Belgium)